GH Research (NASDAQ:GHRS) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of GH Research (NASDAQ:GHRS) in a research note issued to investors on Thursday, Benzinga reports. They currently have a $40.00 price objective on the stock.

Separately, JMP Securities reissued a market outperform rating and issued a $39.00 price target on shares of GH Research in a report on Wednesday.

GH Research Price Performance

Shares of GH Research stock opened at $8.23 on Thursday. The firm has a market capitalization of $428.19 million, a PE ratio of -13.27 and a beta of 0.83. The company’s fifty day moving average price is $11.11 and its two-hundred day moving average price is $11.19. GH Research has a 52-week low of $5.05 and a 52-week high of $14.99.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.03. Analysts predict that GH Research will post -0.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GH Research

Several large investors have recently made changes to their positions in GHRS. AdvisorShares Investments LLC grew its holdings in shares of GH Research by 4.3% in the 4th quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock worth $280,000 after purchasing an additional 1,977 shares during the last quarter. Lynx1 Capital Management LP grew its holdings in shares of GH Research by 80.1% in the 1st quarter. Lynx1 Capital Management LP now owns 3,310,563 shares of the company’s stock worth $35,291,000 after purchasing an additional 1,471,946 shares during the last quarter. BVF Inc. IL grew its holdings in shares of GH Research by 12.1% in the 4th quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock worth $60,321,000 after purchasing an additional 1,125,000 shares during the last quarter. Finally, RA Capital Management L.P. grew its holdings in shares of GH Research by 11.9% in the 1st quarter. RA Capital Management L.P. now owns 6,251,714 shares of the company’s stock worth $66,643,000 after purchasing an additional 664,381 shares during the last quarter. Institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).